• Thurs news: GSK inks 2nd neuro pact in weeks. Teva episodic migraine trial. FDA clears AZ’s Imfinzi for aggressive lung cancer. Novartis fails to block generic Entresto. Nuvig gets immune drug funding. See more on our front page

Key account manager

























You’re not missing much if you’re not getting hired- they want to pay people like primary care reps. Definitely not rare disease $. The drug is a 40 yr old diet drug fen-phen. Move on to better opportunities folks.
 
























Has anyone received offer and start date?? I’m hoping for final interview, but haven’t heard past HR and first zoom and follow up email. Hey a low base is better than starting the year still in laidoff-land.
 






Has anyone received offer and start date?? I’m hoping for final interview, but haven’t heard past HR and first zoom and follow up email. Hey a low base is better than starting the year still in laidoff-land.

I used to work at Zogenix when it was a startup selling Sumavel DosePro. The culture back then was amazing. Can I ask what type of salaries they are throwing out there?
 


















Mgmt trying to spin this as rare disease but Epilepsy does not fit that category. It’s specialty pharma and pays like specialty pharma too. True rare disease pays as high as 165k base.
 






Try 165-195k base for current rare disease/ultra rare disease base pay. I’ve been interviewing a lot lately and this is the going rate for a good start-up biotech company in the Rare Disease space.
 






























i agree. Initial reports were this would be a game changer for LGS but now it’s seeming like a mediocre product.

And this will likely have a REM. No matter how we twist it, it will be a pain for the offices. I’ve sold meds with REMs, but they were very efficacious and safe. So offices were willing to use it with a select population. I’m concerned payers aren’t going to cover this product well because of all the above. I guess I better keep my resume circulating.